Pharmaceutical

STAT Morning Rounds: Six health news stories you need to start your day

STAT Morning Rounds: Six health news stories you need t...

Dec 5, 2023

Understand how science, health policy, and medicine shape the world everyday. Si...

STAT+: Pfizer plans to depart BIO

STAT+: Pfizer plans to depart BIO

Dec 5, 2023

The pharmaceutical giant Pfizer plans to exit the Biotechnology Innovation Organ...

STAT+: CVS’s new drug payment plan won’t lower patients’ prices, experts warn

STAT+: CVS’s new drug payment plan won’t lower patients...

Dec 5, 2023

Drug pricing experts said CVS’ new program appears designed to pad CVS’ own bott...

STAT+: Senate panel considers Medicare policy fixes to drug shortages

STAT+: Senate panel considers Medicare policy fixes to ...

Dec 5, 2023

Drug shortage fixes have eluded Congress, and a Senate panel heard about Medicar...

STAT+: $100 billion estimate for Ozempic-style weight loss drugs gets wary eye from analysts

STAT+: $100 billion estimate for Ozempic-style weight l...

Dec 5, 2023

The GLP-1 market is growing quickly. But an analyst noted that with other herald...

STAT+: RNA startup ReNAgade cuts staff seven months after raising $300 million

STAT+: RNA startup ReNAgade cuts staff seven months aft...

Dec 5, 2023

Biotech startup ReNAgade Therapeutics is cutting staff just seven months after r...

ChatGPT doesn’t know much about drugs, Hims & Hers enters weight-loss market

ChatGPT doesn’t know much about drugs, Hims & Hers ente...

Dec 5, 2023

In the latest edition of STAT's health tech newsletter: ChatGPT doesn't know muc...

STAT Morning Rounds: The health news you need to read today

STAT Morning Rounds: The health news you need to read t...

Dec 5, 2023

Understand how science, health policy, and medicine shape the world everyday. Si...

Carmot’s chance of beating the odds in the biotech market just ended

Carmot’s chance of beating the odds in the biotech mark...

Dec 5, 2023

Want to stay on top of the science and politics driving biotech today? Sign up t...

Aficamten by Cytokinetics for Diastolic Heart Failure (...

Dec 4, 2023

Aficamten is under clinical development by Cytokinetics and currently in Phase I...

TTI-101 by Tvardi Therapeutics for Head And Neck Squamo...

Dec 4, 2023

TTI-101 is under clinical development by Tvardi Therapeutics and currently in Ph...

Ketamine ER by Douglas Pharmaceuticals for Major Depres...

Dec 4, 2023

Ketamine ER is under clinical development by Douglas Pharmaceuticals and current...

SIM-325 by TCR Cure Biopharma Technology for Head And N...

Dec 4, 2023

SIM-325 is under clinical development by TCR Cure Biopharma Technology and curre...

Latozinemab by Alector for Frontotemporal Dementia (FTD): Likelihood of Approval

Latozinemab by Alector for Frontotemporal Dementia (FTD...

Dec 4, 2023

Latozinemab is under clinical development by Alector and currently in Phase III ...

SGN-1 by Guangzhou Sinogen Pharmaceutical for Head And ...

Dec 4, 2023

SGN-1 is under clinical development by Guangzhou Sinogen Pharmaceutical and curr...

RiMO-301 by Rimo Therapeutics for Recurrent Head And Ne...

Dec 4, 2023

RiMO-301 is under clinical development by Rimo Therapeutics and currently in Pha...